How Leqembi and Kisunla Fight Alzheimer's in Different Ways
A diagnosis of Alzheimer's no longer means there are no treatment options. Two FDA-approved drugs, Leqembi and Kisunla, can slow the disease for people diagnosed early, but they work differently. Understanding how beta-amyloid changes from harmless protein fragments into toxic oligomers, protofibrils, plaques, and eventually tau tangles can help patients and families make more informed treatment decisions.
Leqembi Does Much More Than Remove Plaque
Most people think Leqembi simply removes amyloid plaque. The science tells a much bigger story. Researchers now believe tiny beta-amyloid oligomers begin damaging synapses and disrupting the brain's glutamate-GABA balance years before plaques appear. Understanding how Leqembi targets these toxic proteins changed the way I think about Alzheimer's disease, and why early treatment matters.
Hearing Loss and Alzheimer’s: What Every Senior Need to Know
Many people think hearing loss only affects their ears, but the greatest damage may occur in the brain. Discover how untreated hearing loss increases cognitive load, drains cognitive reserve, raises dementia risk, and why properly fitted hearing aids can help your brain stay healthier, sharper, and more resilient.
Leqembi = Plaque Free Brain and a Promising Future
Imagine being told you have Alzheimer's disease—and then, two years later, learning that the beta-amyloid plaques once filling your brain are no longer detectable on a PET scan. Until recently, that outcome would have seemed impossible. Thanks to early diagnosis and treatment with Leqembi, it became my reality. This is not a story about a cure. It is a story about what can happen when Alzheimer's is detected early enough for today's disease-modifying treatments to make a difference. It is also a story of gratitude—to the scientists who made this breakthrough possible—and a reminder that every adult over 60 should ask for a cognitive assessment before symptoms become impossible to ignore.
How Leqembi’s Multi-Target Strategy Fights Alzheimer’s
For decades, Alzheimer's treatments could do little more than ease symptoms while the disease continued its relentless attack on the brain. Leqembi represents a different approach. Rather than simply treating the consequences of Alzheimer's, it targets the disease itself by attaching to harmful beta-amyloid proteins at multiple stages of their development—from the smallest, most toxic clusters to fully formed plaques. By interrupting this destructive process early and continuing to remove existing amyloid, Leqembi gives the brain a better opportunity to protect neurons, preserve memory, and maintain the connections that define who we are. Understanding why this matters begins with understanding how Alzheimer's damages the brain.
You Have to Ask for a MCI Test
Most doctors won't suggest that you have your memory tested during your annual physical. If you want to know whether your brain is as healthy as the rest of your body, YOU HAVE TO ASK.
We spend our lives scheduling physicals, blood tests, eye exams, and even dental cleanings, yet the most vital organ in our body, the brain, often goes unchecked. Imagine discovering years too late that something could have been done to delay Alzheimer’s, if only you had asked for a simple test.
Where Did My Short-Term Memory Go?
Discover why short-term and working memory problems persist after Leqembi treatment and learn practical, science-based strategies to improve daily function and independence with Alzheimer's.
Why People with Stronger Brains Are at RISK for Undiagnosed Alzheimer’s
If you've always been the person who solved problems, learned new skills, remembered details, and adapted to life's challenges, you probably think your brain is one of your greatest strengths. And it is. But that very strength, high cognitive reserve, may also put you at greater risk of living with undiagnosed Alzheimer's disease.